secwatch.observer — SEC 8-K summary
======================================

Issuer:     KINETA, INC./DE (—)
CIK:        0001445283
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0000950170-24-022632
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.05, 7.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kineta cuts 64% of staff, halts trial enrollment, explores strategic alternatives
--------------------------------------------------------------------------------

- Workforce reduced by 64% (7 employees), including CEO Shawn Iadonato and GC Pauline Kenny, effective March 1, 2024.
- CEO and GC transition to consultants through Dec 2024; unvested equity continues to vest; Iadonato stays on board.
- Terminates enrollment in VISTA-101 Phase 1/2 trial for KVA12123; currently enrolled patients may continue.
- Certain investors will not fulfill funding obligations for second tranche of private placement, causing cash insufficiency.
- Exploring sale of assets, sale of company, merger, licensing, or liquidation to maximize shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445283/000095017024022632/0000950170-24-022632-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445283/000095017024022632/ka-20240229.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-022632

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer